Abstract A 22 year old female with Sotos syndrome and a small cell lung carcinoma is described. This case is of interest not only because of the somatic growth pattern, atypical of Sotos syndrome, but also because of the association with a rare tumour. Of significance is the possible role of mutations at 3p21 in the aetiology of Sotos syndrome and tumour development.
. o.. Age (years) Figure 1 Height chart: BA = bone age. 13 15 17 19 There are several published reports of tumour formation in overgrowth syndromes."q Here we describe a patient with Sotos syndrome who died of secondary hepatic tumour deposits at the age of 22 years and where subsequent histological and radiological review indicated that the primary tumour was a small cell lung carcinoma (sclc). The association of Sotos syndrome and sclc could be significant as loss of heterozygosity of markers at chromosome 3p2l has been identified in small cell lung carcinoma5 and an apparently balanced de novo translocation with one of the breakpoints at the same locus, 3p21, has been reported in a child with Sotos syndrome. 6 While the involvement of the same chromosome region in these two cases could be coincidental, it could also indicate the localisation of a gene or genes for Sotos syndrome.
Case report
The patient was delivered by forceps at term plus 10 days. Birth weight and length of 4320 g and 56 cm were above the 97th centile and subsequent accelerated growth resulted in gigantic adult proportions (figs 1 and 2).
Early developmental delay and incoordination were documented in the medical records and unsupported walking was not achieved until 22 (table 2) .
Development of a sclc in the patient is of particular interest as the locus that has been implicated in the development of this tumour, 3p2 1, is the same as one of the breakpoints in a patient with Sotos syndrome and an apparently balanced de novo translocation reported by Schrander-Stumpel et al. 6 Although there are a number of other reports of chromosomal rearrangements in subjects with a 'Sotos-like' phenotype,'9 20 the patient described by Schrander-Stumpel et al6 has the 'classical' Sotos phenotype and therefore the two breakpoints in this case, 6p2l and 3p2l in particular, should be seriously considered as possible localisations for the Sotos gene.
Loss of heterozygosity for markers between 3p21-25 in sclc has been reported by several workers,52' the postulated pathogenetic mechanism being the loss at this locus of a protective or suppressor gene (anti-oncogene) in the tumour, which is present as a single copy in the normal somatic tissue. It Further molecular investigation of the present case is obviously important in order to identify whether heterozygosity for any markers in the blood has been lost in the tumour tissue.2324 To date, this investigation has been hampered by degradation of tumour DNA, most of the DNA extracted being smaller than 2kb, which is only suitable for PCR amplification. In the long term, cloning and sequencing the DNA across the region of the 3p2l translocation and screening a population of patients with Sotos syndrome for mutations in this region would provide a more definitive answer. Unfortunately, efforts to establish a cell line in the above patient were unsuccessful.
Conclusion
The development of tumours in Sotos syndrome appears to be a rare event. However, the occasional association may be important in the understanding of the aetiology of Sotos syndrome. The possibility of alleles at 3p21 being involved in the causation of Sotos syndrome, as well as having a role in the development of tumours, identifies an exciting area for future research. In addition, this case provides information on an unusual pattern of growth and sexual development in Sotos syndrome. It will be important to note if any subsequent cases that develop tumours have a similar growth pattern.
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